Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 49, Issue 6, 2007, Pages 835-840

  Jarfelt, M ^a,c   Kujacic, V ^a   Holmgren, D ^a   Bjarnason, R ^a,b   Lannering, B ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Anthracyclines; Exercise echocardiography

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GROWTH HORMONE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HEART EJECTION FRACTION; HUMAN; INFANT; LEUKEMIA REMISSION; M MODE ECHOCARDIOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADULT; ANTHRACYCLINES; ECHOCARDIOGRAPHY, DOPPLER; ECHOCARDIOGRAPHY, STRESS; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMAN GROWTH HORMONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RISK FACTORS; SURVIVORS;

EID: 34948852306     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21289     Document Type: Article

References (50)

1. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-2275.
2. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
3. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 2001;19:191-196.
4. Hitchcock-Bryan S, Gelber R, Cassady JR, et al. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:211-215.
5. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004;91:37-44.
6. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-1677.
7. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-2636.
8. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 1997;15:61-68.
9. Davies HA, Didcock E, Didi M, et al. Growth, puberty and obesity after treatment for leukaemia. Acta Paediatr Suppl 1995;411:45-50; discussion 51.
10. Didi M, Didcock E, Davies HA, et al. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127:63-67.
11. Jarfelt M, Lannering B, Bosaeus I, et al. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 2005;153:81-89.
12. Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 2004;89:5003-5012.
13. Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:1359-1365.
14. Talvensaari KK, Lanning M, Tapanainen P, et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 1996;81:3051-3055.
15. Warner JT, Gregory JW, Webb DK. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1995:72:97.
16. Gustafsson G, Kreuger A, Dohlwitz A. Acute lymphoblastic leukemia in Swedish children 1973-1978. Acta Paediatr Scand 1981;70:609-614.
17. Jarfelt M, Bjarnason R, Lannering B. Young adult survivors of childhood acute lymphoblastic leukemia: Spontaneous GH secretion in relation to CNS radiation. Pediatr Blood Cancer 2004;42:582-588.
18. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
19. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensjonal Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
20. Oh JK, Appleton CP, Hatle LK, et al. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997;10:246-270.
21. Appleton CP, Jensen JL, Hatle LK, et al. Doppler evaluation of left and right ventricular diastolic function: A technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997;10:271-292.
22. Pozzoli M, Traversi E, Roelandt JR. Non-invasive estimation of left ventricular filling pressures by Doppler echocardiography. Eur J Echocardiogr 2002;3:75-79.
23. Cooper C, Storer TW. Exercise testing and interpretation. Cambridge, UK: Cambridge University Press; 2001.
24. Froelicher VF. Exercise and the heart 2000.
25. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260-311.
26. Good P. Permutation test. New York: Springer Verlag; 2000.
27. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 2002;13:819-829.
28. Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol 2002;13:503-512.
29. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743.
30. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003;97:1991-1998.
31. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
32. Levitt GA, Dorup I, Sorensen K, et al. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463-468.
33. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study. Pediatr Cardiol 1999;20:252-263.
34. Dorup I, Levitt G, Sullivan I, et al. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. Heart 2004;90:1214-1216.
35. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993;77:1671-1676.
36. Merola B, Cittadini A, Colao A, et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993;77:1658-1661.
37. Beshyah SA, Shahi M, Foale R, et al. Cardiovascular effects of prolonged growth hormone replacement in adults. J Intern Med 1995;237:35-42.
38. Valcavi R, Gaddi O, Zini M, et al. Cardiac performance and mass in adults with hypopituitarism: Effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995;80:659-666.
39. Colao A, Cuocolo A, Di Somma C, et al. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clin Endocrinol (Oxf) 2000;52:447-455.
40. Rosen T, Eden S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:195-200.
41. Rahimi K, Thomas A, Adam M, et al. Implications of exercise test modality on modern prognostic markers in patients with known or suspected coronary artery disease: Treadmill versus bicycle. Eur J Cardiovasc Prev Rehabil 2006;13:45-50.
42. Zhou B, Conlee RK, Jensen R, et al. Stroke volume does not plateau during graded exercise in elite male distance runners. Med Sci Sports Exerc 2001;33:1849-1854.
43. De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996;39:504-512.
44. Lanzarini L, Bossi G, Laudisa ML, et al. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J 2000;140:315-323.
45. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr 2001;160:607-610.
46. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991;68:435-438.
47. Powers SK, Lennon SL, Quindry J, et al. Exercise and cardioprotection. Curr Opin Cardiol 2002;17:495-502.
48. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA 2000;283:3095-3101.
49. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342:454-460.
50. Chicco AJ, Hydock DS, Schneider CM, et al. Low intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol 2005.